From Noncoding Variant to Phenotype via SORT1 at the 1p13 Cholesterol Locus
Musunuru, K., et.al., Nature 2010.pdf (713.3Kb)
Access StatusFull text of the requested work is not available in DASH at this time ("dark deposit"). For more information on dark deposits, see our FAQ.
Lee, Noemi E.
Sachs, Katherine V.
Ruda, Vera M.
Hall, Jennifer L.
Schadt, Eric E.
Morales, Carlos R.
Phillips, Michael C.
Ejebe, Kenechi G.
Krauss, Ronald M.
Rader, Daniel J.Note: Order does not necessarily reflect citation order of authors.
MetadataShow full item record
CitationMusunuru, Kiran, Alanna Strong, Maria Frank-Kamenetsky, Noemi E. Lee, Tim Ahfeldt, Katherine V. Sachs, Xiaoyu Li, et al. 2010. “From Noncoding Variant to Phenotype via SORT1 at the 1p13 Cholesterol Locus.” Nature 466 (7307) (August): 714–719. doi:10.1038/nature09266.
AbstractRecent genome-wide association studies (GWASs) have identified a locus on chromosome 1p13 strongly associated with both plasma low-density lipoprotein cholesterol (LDL-C) and myocardial infarction (MI) in humans. Here we show through a series of studies in human cohorts and human-derived hepatocytes that a common noncoding polymorphism at the 1p13 locus, rs12740374, creates a C/EBP (CCAAT/enhancer binding protein) transcription factor binding site and alters the hepatic expression of the SORT1 gene. With small interfering RNA (siRNA) knockdown and viral overexpression in mouse liver, we demonstrate that Sort1 alters plasma LDL-C and very low-density lipoprotein (VLDL) particle levels by modulating hepatic VLDL secretion. Thus, we provide functional evidence for a novel regulatory pathway for lipoprotein metabolism and suggest that modulation of this pathway may alter risk for MI in humans. We also demonstrate that common noncoding DNA variants identified by GWASs can directly contribute to clinical phenotypes.
Citable link to this pagehttp://nrs.harvard.edu/urn-3:HUL.InstRepos:34903179
- FAS Scholarly Articles